Federation of Clinical Immunology Societies goes South 2021: Advanced Course on Molecular and Cellular Translational Immunology

Abstract

The Federation of Clinical Immunology Societies (FOCIS) regularly organizes scientific meetings to foster advances in immunology. A new event of this type is FOCIS Goes South, a course and workshop organized by FOCIS Centers of Excellence (FCEs) from across Latin America, which consists of a course on advanced immunology, a flow cytometry workshop and seminars on cutting-edge research in autoimmunity, tolerance, cancer, infectious diseases and vaccines. Due to the COVID-19 pandemic, the second version of FOCIS Goes South, hosted by the Millennium Institute on Immunology and Immunotherapy in Chile, took place virtually from 15 to 18 November 2021, with more than 950 registered participants. The present article summarizes the key findings and insights discussed at FOCIS Goes South 2021.

Keywords::

• autoimmunity
• cancer
• flow cytometry
• FOCIS Goes South 2021
• infectious diseases
• tolerance
• translational immunology
• vaccine development

Acknowledgements

The authors would like to thank L Leiva and J Olavarría of Pontificia Universidad Católica de Chile for organizing the conference.

Financial & competing interests disclosure

Funding was received from BD Biosciences, Instituto Milenio en Inmunología e Inmunoterapia, International Centre of Genetic Engineering and Biotechnology (ICGEB) and Pontificia Universidad Católica de Chile. I Anegon has patents and is a founder of AbolerIS Pharma, which develops anti-CD45RC mAb for the treatment of autoimmune diseases. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

Funding was received from BD Biosciences, Instituto Milenio en Inmunología e Inmunoterapia, International Centre of Genetic Engineering and Biotechnology (ICGEB) and Pontificia Universidad Católica de Chile. I Anegon has patents and is a founder of AbolerIS Pharma, which develops anti-CD45RC mAb for the treatment of autoimmune diseases. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.